One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

doi:10.12998/wjcc.v10.i28.10085

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3546)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

157

WORD

HTML

1616

Figures (1-3)

365

Tables (1-3)

290

Sum=2461

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

298

Download

787

Sum=1085

Oct 6, 2022 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085

Table 2 Reduction of hepatitis B virus DNA levels of chronic hepatitis B patients at weeks 168 and 192 (mean SD, log₁₀IU/mL)

Group	HBeAg-positive		HBeAg-negative
Group	168 wk	192 wk	168 wk	192 wk
A	6.44 ± 1.39	6.61 ± 1.28	5.73 ± 1.25	6.05 ± 1.20
B	6.53 ± 1.24	6.69 ± 1.12	5.99 ± 1.47	6.03 ± 1.49
P	0.654	0.696	0.533	0.952

CHB: Chronic hepatitis B; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus.

Citation: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096
URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10085